Determine the level of patient’s satisfaction of endoscopy using EMLA cream, EMLA gel, Lidocaine gel, Lidocaine spray and placebo gel

Comparison of the effects of prescription EMLA cream before endoscopy to reduce pain and increase the satisfaction of patients during and after endoscopy, with the effect EMLA gel, Lidocaine gel, Lidocaine spray and placebo gel in endoscopy patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201509136480N9

Enrollment

150

Registered

2015-10-24

Start date

2006-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain and dissatisfaction during upper gastrointestinal endoscopy. Other diseases of the digestive system

Interventions

Intervention 1: Intervention group 1: The EMLA cream are used five minutes before the endoscopy for Group A (manufactured by AstraZeneca), the dose is 5 g in posterior part of the tongue. Intervention

Treatment - Drugs

Placebo

Intervention group 1: The EMLA cream are used five minutes before the endoscopy for Group A (manufactured by AstraZeneca), the dose is 5 g in posterior part of the tongue.

Intervention group 2: The EMLA gel are used five minutes before the endoscopy for Group B (manufactured by AstraZeneca), the dose is 5 g in posterior part of the tongue.

Intervention group 3: The Lidocaine gel are used five minutes before the endoscopy for Group C (manufactured by AstraZeneca), the dose is 5 g in posterior part of the tongue.

Intervention group 4: The Lidocaine spray 1% are used five minutes before the endoscopy for Group D (manufactured by AstraZeneca), the dose is 3 puffs in posterior part of the tongue.

Intervention group 5: The placebo gel are used five minutes before the endoscopy for Group E (manufactured by AstraZeneca), the dose is 5 g in posterior part of the tongue.

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: upper gastrointestinal endoscopy in these patients should be a non-emergency; the patients have given consent for endoscopy; no history of upper gastrointestinal endoscopy. Exclusion criteria: age under 12 years; lack of consent patient; patients with acute gastrointestinal bleeding; bedridden patients.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The satisfaction of patients of endoscopy. Timepoint: During and after endoscopy. Method of measurement: GHAA-9 questionnaire.	—

Secondary

Measure	Time frame
The pain and discomfort in the throat and neck area. Timepoint: During and after endoscopy. Method of measurement: GHAA-9 questionnaire.;Vomiting or retching evaluate. Timepoint: During and after endoscopy. Method of measurement: GHAA-9 questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr Jafar Nasiri

Shahrekord University of Medical Sciences

jhnasiri@yahoo.com+98 38 3333 2907

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026